TRCT
CGON icon

Tower Research Capital (TRC)’s CG Oncology CGON Stock Holding History

Tower Research Capital (TRC)’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Sell
3,567
-4,720
-57% -$309K 0.01% 1517
2026
Q1 		$561K Buy
8,287
+7,904
+2,064% +$448K 0.01% 829
2025
Q4 		$15.9K Sell
383
-1,236
-76% -$51.1K ﹤0.01% 3271
2025
Q3 		$65.2K Sell
1,619
-5,363
-77% -$156K ﹤0.01% 2318
2025
Q2 		$182K Buy
6,982
+4,288
+159% +$103K ﹤0.01% 1867
2025
Q1 		$66K Sell
2,694
-6,171
-70% -$174K ﹤0.01% 2026
2024
Q4 		$254K Buy
8,865
+8,541
+2,636% +$292K 0.01% 1551
2024
Q3 		$12.2K Sell
324
-4,803
-94% -$168K ﹤0.01% 3610
2024
Q2 		$162K Buy
5,127
+5,089
+13,392% +$176K ﹤0.01% 2231
2024
Q1 		$1.67K Buy
+38
New +$1.55K ﹤0.01% 5211

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tower Research Capital (TRC)'s CGON Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its CG Oncology (CGON) stake by 57% in Q2 2026, selling an estimated $309K and leaving 3,567 shares worth $253K. The position accounts for 0.01% of the portfolio, ranked #1517.

Tower Research Capital (TRC) first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. The position peaked at $561K in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Tower Research Capital (TRC) held 3,567 shares of CG Oncology worth $253K as of Q2 2026.
  • Tower Research Capital (TRC) sold 4,720 CG Oncology shares in Q2 2026, an estimated $309K.
  • CG Oncology made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1517 holding.
  • Tower Research Capital (TRC) first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • Tower Research Capital (TRC)'s CG Oncology position peaked at $561K in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.